NanoViricides
NNVC
27 hedge funds and large institutions have $4.77M invested in NanoViricides in 2013 Q4 according to their latest regulatory filings, with 24 funds opening new positions, increasing their positions, reducing their positions, and closing their positions.
941% more capital invested
Capital invested by funds: $458K → $4.77M (+$4.31M)
800% more funds holding
Funds holding: 3 → 27 (+24)
100% less call options, than puts
Call options by funds: $0 | Put options by funds: $215K
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Goldman Sachs
New York
|
+$1.02M |
| 2 |
CG
Colony Group
Boston,
Massachusetts
|
+$735K |
| 3 |
Bank of America
Charlotte,
North Carolina
|
+$695K |
| 4 |
Vanguard Group
Malvern,
Pennsylvania
|
+$570K |
| 5 |
VKH
Virtu KCG Holdings
New York
|
+$274K |
Top Sellers
NNVC Hedge Fund Activity: Q4 2013 in Review
27 of the 3,459 institutional investors tracked by Wall St. Rank reported a position in NanoViricides (NNVC) for Q4 2013, worth a combined $4.77M — up 941% from $458K a quarter earlier.
Buyers outnumbered sellers: 24 funds opened new NNVC positions and 0 closed out — a net gain of 24 holders — while 0 added to existing stakes and 0 trimmed.
The largest buyer was Goldman Sachs, opening a new position worth an estimated $1.02M.
- 27 institutional investors held NanoViricides (NNVC) as of Q4 2013, up from 3 in Q3 2013.
- Funds reported $4.77M of NanoViricides stock for Q4 2013, up 941% quarter-over-quarter.
- 24 funds opened new NanoViricides positions in Q4 2013 and 0 closed out, a net change of +24 holders.
- The largest NanoViricides buyer in Q4 2013 was Goldman Sachs, an estimated $1.02M added.
Based on aggregated 13F filings for Q4 2013.